N Hijiya

Summary

Affiliation: St. Jude Children's Research Hospital
Country: USA

Publications

  1. ncbi request reprint Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 18:1581-6. 2004
  2. ncbi request reprint Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia
    Nobuko Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 44:63-9. 2005
  3. ncbi request reprint Utility of automated counting to determine absolute neutrophil counts and absolute phagocyte counts for pediatric cancer treatment protocols
    Nobuko Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 101:2681-6. 2004
  4. ncbi request reprint Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:1399-403. 2005
  5. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007
  6. pmc Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Blood 108:3997-4002. 2006
  7. pmc Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study
    J T Sandlund
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1127-30. 2009
  8. ncbi request reprint Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
    E Coustan-Smith
    Department of Hematology Oncology, Children s Research Hospital, Memphis, TN, USA
    Leukemia 18:499-504. 2004
  9. pmc Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia
    J C Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 86:651-8. 2009
  10. ncbi request reprint Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000
    R C Ribeiro
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:2125-9. 2005

Detail Information

Publications16

  1. ncbi request reprint Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 18:1581-6. 2004
    ..0+/-9.6% for those with late relapse and 20.0+/-8.0% for those with early relapse. We conclude that low-dose etoposide administered orally has a cytoreductive effect in relapsed ALL...
  2. ncbi request reprint Severe cardiopulmonary complications consistent with systemic inflammatory response syndrome caused by leukemia cell lysis in childhood acute myelomonocytic or monocytic leukemia
    Nobuko Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Pediatr Blood Cancer 44:63-9. 2005
    ..Life-threatening pulmonary complications that coincide with cell lysis during early chemotherapy and that mimic systemic inflammatory response syndrome (SIRS) have been reported in patients with acute myeloid leukemia (AML)...
  3. ncbi request reprint Utility of automated counting to determine absolute neutrophil counts and absolute phagocyte counts for pediatric cancer treatment protocols
    Nobuko Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Cancer 101:2681-6. 2004
    ..By analyzing blood samples from children undergoing cancer treatment, the authors determined whether ANCs and APCs obtained by automated methods correlated positively with ANCs and APCs obtained manually...
  4. ncbi request reprint Overt testicular disease at diagnosis of childhood acute lymphoblastic leukemia: lack of therapeutic role of local irradiation
    N Hijiya
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:1399-403. 2005
    ..In conclusion, the prognostic impact of overt testicular disease has diminished. Irradiation appears to provide no survival advantage to this patient population...
  5. ncbi request reprint Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    JAMA 297:1207-15. 2007
    ..Little is known about the incidence of secondary neoplasms after 15 to 20 years in children and adolescents who were treated for acute lymphoblastic leukemia...
  6. pmc Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, 332 North Lauderdale St, Memphis, TN 38105 2794, USA
    Blood 108:3997-4002. 2006
    ..Further, the systemic clearance of methotrexate, teniposide, etoposide, and cytarabine did not differ with BMI (P > .3). We conclude that BMI does not affect the outcome or toxicity of chemotherapy in this patient population with ALL...
  7. pmc Effective treatment of advanced-stage childhood lymphoblastic lymphoma without prophylactic cranial irradiation: results of St Jude NHL13 study
    J T Sandlund
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Leukemia 23:1127-30. 2009
    ..The treatment described here produces high cure rates in children with lymphoblastic lymphoma without the use of prophylactic cranial irradiation...
  8. ncbi request reprint Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse
    E Coustan-Smith
    Department of Hematology Oncology, Children s Research Hospital, Memphis, TN, USA
    Leukemia 18:499-504. 2004
    ..We conclude that MRD assays should be used to guide the selection of postremission therapy in patients with ALL in first relapse...
  9. pmc Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia
    J C Panetta
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, Tennessee, USA
    Clin Pharmacol Ther 86:651-8. 2009
    ..At relapse, there were significant pharmacokinetic and pharmacodynamic differences attributable to ASP preparation and antibody status...
  10. ncbi request reprint Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000
    R C Ribeiro
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Leukemia 19:2125-9. 2005
    ..We conclude that subtype-specific therapies are needed to replace the 'one size fits all' strategy of the past two decades...
  11. ncbi request reprint Risk of adverse events after completion of therapy for childhood acute lymphoblastic leukemia
    Ching Hon Pui
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:7936-41. 2005
    ..Our goal was to use the information to further refine therapy and advance cure rates...
  12. ncbi request reprint Patient-reported outcomes in end-of-life research in pediatric oncology
    Pamela S Hinds
    St Jude Children s Research Hospital, Memphis, TN 38105 2719, USA
    J Pediatr Psychol 32:1079-88. 2007
    ....
  13. doi request reprint Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse
    Nobuko Hijiya
    Department of Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Cancer 112:1983-91. 2008
    ..The authors evaluated the response rate, toxicity, and pharmacokinetics of topotecan given before standard induction therapy for childhood acute lymphoblastic leukemia (ALL) in first relapse...
  14. ncbi request reprint Lack of benefit of early detection of relapse after completion of therapy for acute lymphoblastic leukemia
    Jeffrey E Rubnitz
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105, USA
    Pediatr Blood Cancer 44:138-41. 2005
    ..We therefore sought to determine if detection of relapse by blood counts before the onset of symptoms provided any clinical benefit...
  15. pmc Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia
    Sima Jeha
    Department of Hematology Oncology, St Jude Children s Research Hospital, 332 N Lauderdale St, Memphis, TN 38105, USA
    Blood 108:3302-4. 2006
    ..9% versus 78% +/- 3.1% (P = .08). These data suggest that CD20 expression is not associated with inferior outcome in pediatric patients treated with contemporary regimens...
  16. pmc Ancestry and pharmacogenetics of antileukemic drug toxicity
    Shinji Kishi
    Department of Pharmaceutical Sciences, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    Blood 109:4151-7. 2007
    ..026). The genotype-phenotype associations were similar whether analyses were adjusted by self-reported race or ancestry-informative genetic markers. Germ-line polymorphisms are significant determinants of toxicity of antileukemic therapy...